Sep 5, 2024   SOURCE: PR NewsWire

SageMedic Corp. Announces Formation of its Scientific and Medical Advisory Board to Significantly Advance Precision Medicine for Cancer Patients

PALO ALTO, Calif., Sept. 5, 2024 /PRNewswire/ -- SageMedic Corp (also known as 'SAGE'), a Silicon Valley-based rising star in cancer diagnostics, is excited to announce the formation of its Scientific and Medical Advisory Board (SAB). Comprised of distinguished authorities in cancer research and medical and surgical oncology, the board reflects SageMedic's commitment to significantly enhance the precision of cancer diagnostics by enabling oncologists to more effectively tailor therapies to individual patient needs.

    --  William Cance, MD, former Chief Medical and Scientific Officer at the
        American Cancer Society, leads the Scientific and Medical Advisory
        Board. According to Dr. Cance, "Cancer poses profound challenges, with
        many advancements offering only marginal benefits to patients. However,
        SAGE's innovative approach--testing cancer therapy options on the
        patient's own live tumor tissue with in vitro results in just 7-10
        days--holds the promise of a transformational advancement in precision
        medicine with dramatically improved patient outcomes."
    --  Jorg Dietrich, MD, PhD, MBA, Director of the Cancer & Neurotoxicity
        Clinic and Brain Repair Research Program at Massachusetts General
        Hospital (MGH) and Harvard Medical School, is a leading voice in
        glioblastoma, brain tumor biology, and cancer therapy.
    --  Amer Karam, MD, Clinical Professor and Director of Robotic Surgery in
        Gynecologic Oncology at Stanford University, is an esteemed gynecologic
        oncologist with longstanding interest in chemosensitivity testing and
        expertise in minimally invasive cancer surgery, advising and
        collaborating with SAGE in ovarian cancer.
    --  Scott Kopetz, MD, PhD, Deputy Chair for Translational Research in the
        Department of Gastrointestinal (GI) Medical Oncology at MD Anderson
        Cancer Center, is known for his translational research in
        gastrointestinal cancers, including in-vitro organoid models.
    --  Priya Kumthekar, MD, Associate Professor of Neurology at the
        Northwestern University Feinberg School of Medicine, is focused on
        innovative therapeutic approaches for central nervous system (CNS)
        malignancies, including primary and metastatic brain tumors.
    --  Konstantinos Votanopoulos, MD, PhD, Professor of Surgery at Atrium
        Health Wake Forest Baptist Comprehensive Cancer Center and Director of
        the Organoid Research Center at Wake Forest University, collaborates
        with SAGE in predicting response to immuno-oncology therapeutics.

Chris Apfel, MD, MBA, Chair & CEO of SageMedic, expressed his enthusiasm: "We are honored to have such a prestigious group of key opinion leaders join our SAB. Their unparalleled expertise will continue to push the boundaries of what is possible in precision medicine to truly personalize therapies for cancer patients."

About SageMedic Corp:

SageMedic Corp is at the forefront of developing diagnostic solutions that significantly improve treatment outcomes in oncology. Through the innovative SAGE Oncotest(TM), an AI-augmented, in-vitro, live 3D microtumor approach, the company provides actionable insights that allow oncologists to devise personalized treatment strategies, enhancing the quality of life for cancer patients across the globe.

For inquiries or further information about SageMedic, please direct communications to:

Mara Quigley, Co-President, Steve Allen Media
(661) 255-8283
382796@email4pr.com
https://SteveAllenMedia.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/sagemedic-corp-announces-formation-of-its-scientific-and-medical-advisory-board-to-significantly-advance-precision-medicine-for-cancer-patients-302239388.html

SOURCE SageMedic Corp